Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for European expansion.

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Get Our Latest Stock Report on GSK GSK Stock Up 0.8 % GSK opened at $35.35 on Friday. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The firm’s 50 day simple moving average is ...

Cancer has long been one of the most feared diseases in the world. Now, a groundbreaking development in vaccine technology ...

New Zealand said late on Thursday that it would make a commitment that by 2035 the country would have reduced emissions by 51 ...

New Zealand plans to introduce legislation before the end of the year that will create a framework to help communities and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

WELLINGTON, New Zealand — A mountain in New Zealand considered an ancestor by Indigenous people was recognized as a legal person Thursday after a new law granted it all the rights and ...

Gene technology has been earmarked for expansion in New Zealand, but without robust regulation local communities could be ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

New Nielsen data reveals NZ’s top automotive advertisers investing $124M, with Nissan surging and 22% of Kiwis planning new ...